AMPHASTAR PHARMACEUTICALS IN (AMPH) Fundamental Analysis & Valuation

NASDAQ:AMPH • US03209R1032

Current stock price

21.36 USD
+0.99 (+4.86%)
At close:
21.36 USD
0 (0%)
After Hours:

This AMPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. AMPH Profitability Analysis

1.1 Basic Checks

  • In the past year AMPH was profitable.
  • In the past year AMPH had a positive cash flow from operations.
  • AMPH had positive earnings in each of the past 5 years.
  • AMPH had a positive operating cash flow in each of the past 5 years.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

1.2 Ratios

  • The Return On Assets of AMPH (6.02%) is better than 86.91% of its industry peers.
  • With an excellent Return On Equity value of 12.44%, AMPH belongs to the best of the industry, outperforming 86.91% of the companies in the same industry.
  • The Return On Invested Capital of AMPH (7.81%) is better than 86.91% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AMPH is below the industry average of 13.10%.
Industry RankSector Rank
ROA 6.02%
ROE 12.44%
ROIC 7.81%
ROA(3y)8.41%
ROA(5y)9.36%
ROE(3y)18.58%
ROE(5y)17.39%
ROIC(3y)10.83%
ROIC(5y)11.23%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20

1.3 Margins

  • AMPH's Profit Margin of 13.63% is amongst the best of the industry. AMPH outperforms 86.91% of its industry peers.
  • AMPH's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 19.50%, AMPH belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
  • In the last couple of years the Operating Margin of AMPH has grown nicely.
  • With a decent Gross Margin value of 49.46%, AMPH is doing good in the industry, outperforming 63.87% of the companies in the same industry.
  • AMPH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 19.5%
PM (TTM) 13.63%
GM 49.46%
OM growth 3Y-3.26%
OM growth 5Y44.05%
PM growth 3Y-9.39%
PM growth 5Y102.5%
GM growth 3Y-0.28%
GM growth 5Y3.84%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. AMPH Health Analysis

2.1 Basic Checks

  • AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • AMPH has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for AMPH has been reduced compared to 5 years ago.
  • Compared to 1 year ago, AMPH has an improved debt to assets ratio.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • AMPH has an Altman-Z score of 2.31. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • AMPH has a Altman-Z score of 2.31. This is in the better half of the industry: AMPH outperforms 60.21% of its industry peers.
  • AMPH has a debt to FCF ratio of 5.13. This is a neutral value as AMPH would need 5.13 years to pay back of all of its debts.
  • The Debt to FCF ratio of AMPH (5.13) is better than 83.25% of its industry peers.
  • AMPH has a Debt/Equity ratio of 0.77. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
  • AMPH's Debt to Equity ratio of 0.77 is on the low side compared to the rest of the industry. AMPH is outperformed by 72.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.13
Altman-Z 2.31
ROIC/WACC0.92
WACC8.51%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • AMPH has a Current Ratio of 4.02. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AMPH (4.02) is comparable to the rest of the industry.
  • A Quick Ratio of 2.90 indicates that AMPH has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.90, AMPH perfoms like the industry average, outperforming 52.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 2.9
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. AMPH Growth Analysis

3.1 Past

  • AMPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.80%.
  • Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 38.40% on average per year.
  • The Revenue has decreased by -1.65% in the past year.
  • Measured over the past years, AMPH shows a quite strong growth in Revenue. The Revenue has been growing by 15.53% on average per year.
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
Revenue 1Y (TTM)-1.65%
Revenue growth 3Y12.99%
Revenue growth 5Y15.53%
Sales Q2Q%-1.83%

3.2 Future

  • The Earnings Per Share is expected to decrease by -1.20% on average over the next years.
  • AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.48% yearly.
EPS Next Y3.08%
EPS Next 2Y4.66%
EPS Next 3Y4.96%
EPS Next 5Y-1.2%
Revenue Next Year4.06%
Revenue Next 2Y4.41%
Revenue Next 3Y4.13%
Revenue Next 5Y4.48%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. AMPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 6.57, which indicates a rather cheap valuation of AMPH.
  • AMPH's Price/Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 94.76% of the companies in the same industry.
  • AMPH is valuated cheaply when we compare the Price/Earnings ratio to 26.86, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 6.38 indicates a rather cheap valuation of AMPH.
  • Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 94.24% of the companies in the same industry.
  • AMPH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 37.39.
Industry RankSector Rank
PE 6.57
Fwd PE 6.38
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • AMPH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMPH is cheaper than 96.34% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 94.76% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.14
EV/EBITDA 5.78
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AMPH does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)2.14
PEG (5Y)0.17
EPS Next 2Y4.66%
EPS Next 3Y4.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMPH Dividend Analysis

5.1 Amount

  • AMPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMPH Fundamentals: All Metrics, Ratios and Statistics

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (4/13/2026, 4:10:06 PM)

After market: 21.36 0 (0%)

21.36

+0.99 (+4.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-05
Inst Owners76.54%
Inst Owner Change-0.23%
Ins Owners10.07%
Ins Owner Change4.02%
Market Cap969.10M
Revenue(TTM)719.89M
Net Income(TTM)98.09M
Analysts76.92
Price Target29.58 (38.48%)
Short Float %11.01%
Short Ratio7.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.91%
Min EPS beat(2)-22.4%
Max EPS beat(2)10.58%
EPS beat(4)3
Avg EPS beat(4)1.57%
Min EPS beat(4)-22.4%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)2.84%
EPS beat(12)8
Avg EPS beat(12)9.98%
EPS beat(16)11
Avg EPS beat(16)14.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.97%
Min Revenue beat(2)-5.76%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.93%
Min Revenue beat(4)-5.76%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-1.61%
Revenue beat(12)5
Avg Revenue beat(12)-0.48%
Revenue beat(16)8
Avg Revenue beat(16)-0.12%
PT rev (1m)-8.14%
PT rev (3m)-8.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.96%
EPS NY rev (1m)-0.84%
EPS NY rev (3m)-10.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.01%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)-1.03%
Valuation
Industry RankSector Rank
PE 6.57
Fwd PE 6.38
P/S 1.35
P/FCF 8.14
P/OCF 6.21
P/B 1.23
P/tB 4.35
EV/EBITDA 5.78
EPS(TTM)3.25
EY15.22%
EPS(NY)3.35
Fwd EY15.68%
FCF(TTM)2.62
FCFY12.28%
OCF(TTM)3.44
OCFY16.11%
SpS15.87
BVpS17.39
TBVpS4.91
PEG (NY)2.14
PEG (5Y)0.17
Graham Number35.66
Profitability
Industry RankSector Rank
ROA 6.02%
ROE 12.44%
ROCE 9.54%
ROIC 7.81%
ROICexc 9.67%
ROICexgc 18.47%
OM 19.5%
PM (TTM) 13.63%
GM 49.46%
FCFM 16.53%
ROA(3y)8.41%
ROA(5y)9.36%
ROE(3y)18.58%
ROE(5y)17.39%
ROIC(3y)10.83%
ROIC(5y)11.23%
ROICexc(3y)13.25%
ROICexc(5y)14.34%
ROICexgc(3y)28.69%
ROICexgc(5y)24.19%
ROCE(3y)13.23%
ROCE(5y)13.72%
ROICexgc growth 3Y-3.07%
ROICexgc growth 5Y50.2%
ROICexc growth 3Y-19.69%
ROICexc growth 5Y34.74%
OM growth 3Y-3.26%
OM growth 5Y44.05%
PM growth 3Y-9.39%
PM growth 5Y102.5%
GM growth 3Y-0.28%
GM growth 5Y3.84%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.13
Debt/EBITDA 3.09
Cap/Depr 65.49%
Cap/Sales 5.16%
Interest Coverage 6.05
Cash Conversion 79.21%
Profit Quality 121.3%
Current Ratio 4.02
Quick Ratio 2.9
Altman-Z 2.31
F-Score6
WACC8.51%
ROIC/WACC0.92
Cap/Depr(3y)81.11%
Cap/Depr(5y)91.09%
Cap/Sales(3y)5.56%
Cap/Sales(5y)5.56%
Profit Quality(3y)111.67%
Profit Quality(5y)103.97%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
EPS Next Y3.08%
EPS Next 2Y4.66%
EPS Next 3Y4.96%
EPS Next 5Y-1.2%
Revenue 1Y (TTM)-1.65%
Revenue growth 3Y12.99%
Revenue growth 5Y15.53%
Sales Q2Q%-1.83%
Revenue Next Year4.06%
Revenue Next 2Y4.41%
Revenue Next 3Y4.13%
Revenue Next 5Y4.48%
EBIT growth 1Y-31.65%
EBIT growth 3Y9.31%
EBIT growth 5Y66.42%
EBIT Next Year6.27%
EBIT Next 3Y3.07%
EBIT Next 5YN/A
FCF growth 1Y-30.96%
FCF growth 3Y22.23%
FCF growth 5Y38.43%
OCF growth 1Y-26.84%
OCF growth 3Y20.52%
OCF growth 5Y22.21%

AMPHASTAR PHARMACEUTICALS IN / AMPH Fundamental Analysis FAQ

What is the fundamental rating for AMPH stock?

ChartMill assigns a fundamental rating of 6 / 10 to AMPH.


What is the valuation status for AMPH stock?

ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.


What is the profitability of AMPH stock?

AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 8 / 10.


Can you provide the financial health for AMPH stock?

The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 7 / 10.